Trials / Unknown
UnknownNCT02206165
A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
A Randomized, Double-blind, Multi-center, Phase 2 Trial to Evaluate the Efficacy and Safety of Candesartan/Amlodipine Combined or Alone and Select Better Dose of CKD-330 in Patients With Essential Hypertension
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 456 (estimated)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Candesartan/Amlodipine combined or alone and select better dose of CKD-330 in essential hypertension patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Candesartan 8mg | Once a day, 8 weeks |
| DRUG | Candesartan 16mg | Once a day, 8 weeks |
| DRUG | Amlodipine 5mg | Once a day, 8 weeks |
| DRUG | Amlodipine 10mg | Once a day, 8 weeks |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-04-01
- Completion
- 2015-06-01
- First posted
- 2014-08-01
- Last updated
- 2015-03-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02206165. Inclusion in this directory is not an endorsement.